In-silico study of Stevia Leaves (Stevia rebaudiana Bertoni) as Antidiabetic Drugs

Resmi Mustarichie1, Effan Junaedi1,2

1Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, 45363 Sumedang, Indonesia.
2Department of Pharmaceutical Chemical Analysis, Faculty of Mathematics and Natural Science, Universitas Garut

ABSTRACT

Diabetes mellitus is a metabolic disorder due to abnormalities in insulin secretion, insulin action or both. Around 200 million people worldwide suffer from diabetes, most of which is type 2 diabetes. One of the targets of diabetes treatment is the DPP-4 enzyme which works to degrade incretin from the body. Sitagliptin, a DPP-4 inhibitor that has been approved for the treatment of type 2 diabetes. Besides using cytotic drugs, biochemical compound can also be used for diabetes therapy, one of which is stevia leaf. This research was conducted to select compounds contained in stevia leaves based on their interaction with DPP4 in silico. The purpose of this study is a potential compound from stevia leaves to be a candidate for antidiabetic drugs. Tests were carried out on DPP4 inhibitors, namely sitagliptin, and 10 compounds contained in stevia leaves. The results show that there are three potential compounds namely isosteviol, stevial and steviolmonoside. Testing the Lipinski's rule of five and pre-ADMET parameters shows that the three compounds have the potential to be used as candidates for antidiabetic drugs.

Keyword: Stevia leaf, Stevia rebaudiana Bertoni, Diabetes mellitus, DPP4, Molecular docking.

ARTICLE INFO: Received 18 sept. 2021; Review Complete; 07 Oct. 2021 Accepted; 25 Nov. 2021 Available online 15 Dec. 2021

Cite this article as:

DOI: http://dx.doi.org/10.22270/ajprd.v9i61042

*Address for Correspondence:
Resmi Mustarichie, Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, 45363 Sumedang, Indonesia.

INTRODUCTION

Diabetes mellitus is a disease or group of metabolic disorders due to abnormalities in insulin secretion, insulin action or both. This condition is characterized by high levels of blood sugar (hyperglycemia) with impaired carbohydrate, protein, and fat metabolism. The result is an increase in oxidative stress which triggers the development of other diseases[1].

WHO estimates that around 200 million people worldwide suffer from Diabetes and this number is likely to double by 2030(Sharma, Joshi, Joshi, Chandra, & Tamta, 2020). Around 90-95% of patients suffer from type 2 diabetes mellitus [2].

According to RISKESDAS data (National Basic Health Research) in 2018 the prevalence of diabetes mellitus at the age of 15 years in Indonesia increased from 6.9% in 2013 to 10.9% in 2018. In addition to the examination of oral glucose tolerance it is known that 30, 8% of respondents experienced impaired fasting blood glucose and 26.3% experienced impaired glucose tolerance, which is stated as a prediabetic condition[3].

Efforts to control diabetes mellitus in patients can also be done in several ways, namely the regulation of diet, exercise, and the use of alternative herbs.

The use of herbs as an alternative has recently increased. Various natural products have been investigated for their effectiveness in treating health problems. Therefore, it is necessary to study effective and potential bioactive compounds that can be used for treatment. One of them is...
an active compound for treating Diabetes with specific molecular targets.

One target of diabetes treatment is the DPP-4 enzyme. Dipeptidyl peptidase-4 (DPP-4) is an adenosine deaminase binding protein that is able to inactivate various oligopeptides. DPP-4 works to degrade incretin from the body, a hormone that regulates insulin secretion after meals to balance blood sugar levels. Thus, compounds that are able to suppress the work of DPP-4 can be an appropriate therapy for type 2 diabetes. DPP-4 inhibitors are the latest antidiabetic class. Some compounds that are classified as DPP-4 inhibitors are sitagliptin, vildagliptin, and saxagliptin, alogliptin, linagliptin, gemigliptin, anagliptin, trelagliptin, omargliptin, evogliptin, and gosogliptin.

Sitagliptin, a DPP-4 inhibitor that was approved for the treatment of type 2 diabetes in the United States in 2006. This drug can be used as monotherapy or in combination therapy with PPARg agonists. Therapy using sitagliptin results in an increase in β cell function and a significant decrease in HbA1c.

Stevia rebaudiana (Bertoni) is a plant that is often used by industry as a natural sweetener instead of synthetic sweeteners. Besides having a sweet taste, stevia also has various benefits including as an antihyperglycemia, antihypertensive, anti-inflammatory, anti-tumor, anti-diarrhea, diuretic effect, and immunomodulatory.

Determination of compound targets by molecular docking is done as an initial screening for finding compounds from stevia leaves that have the potential as antidiabetic. So there will be antidiabetic drug candidates who work as DPP4 inhibitors for the next stage of testing.

MATERIALS AND METHOD

Materials

3D complex DPP4 protein- Novel Heterocyclic DPP4 inhibitor with code 4A5S with RMSD 1.62Å downloaded from Protein Data Bank (www.rscb.org) in pdb format. 3D structure of test ligands (dulcoside A, isosteviol, rebaudioside A, B, C, E, seteviol, steviolmonoside, steviolbioside, stevioside) and comparative ligands (sitagliptin) were obtained from PubChem database with sdf format. This research was conducted using the Autodock Tools 4.0.1 program, Discovery Studio Visualizer 3.5, ChemDraw Ultra 12.

Method

Ligand and receptor complexes are separated using the Discovery Studio program and then stored in pdb format. Energy minimization of the comparative ligands and test ligands was carried out using the Chemdraw Ultra 12 program. The ligands and receptors were then prepared with the Autodock Tools 4.0.1 program by adding hydrogen atoms and the charge then stored in the pdbqt format. Validation is then performed with native ligand redocking of DPP4 receptors with the Autodock Tools 4.0.1 program and the resulting grid parameters are used for the docking of comparative ligands and test ligands. Docking was performed on 1 comparison ligand and 10 test ligands with GA running 100 times. The resulting docking output is in the form of free bond energy (ΔG) and the value of the coefficient of inhibition (Ki). Pharmacokinetics, toxicity and Lipinski’s rule of five tests were conducted online using the sites preadmet.bmdrc.kr and scfbio-iitd.res.in/software/drug-design/lipinski.jsp.

RESULT AND DISCUSSION

The research aims to obtain potential compounds that will be used as drug candidates from Berviai Stevia rebaudiana leaves by predicting their affinity and activity for DPP4 receptors. The DPP4 receptor downloaded, has 2 chains namely A and B. In this study, the selected DPP4 receptor part is chain B.

Validation is performed on the active side of the native ligand on crystallographic results. The validation process is performed on the gridbox coordinate settings x = 25,541; y = 65,708; z = 81,931; 40; with volumes x, y, z = 40 Å. The results of the validation by the redocking method show an RMSD value of 0.463 Å (<2 Å) which indicates that the position of the atoms in the ligand from the redocking result is almost the same as the position in the crystallographic ligand. So the 4A5S receptor can be used for the docking process.

Figure 1: 3D structure of DPP4 protein chain B with code 4A5S

Figure 2. Position of ligand from crystallographic results with redocking results (yellow = crystallographic results and blue = redocking results)
Table 1: Results of validation of native ligands with the DPP4 enzyme

<table>
<thead>
<tr>
<th>Compound</th>
<th>Amino Acid Residue Interactions</th>
<th>RMSD (Å)</th>
<th>ΔG (Kcal/mol)</th>
<th>KI (pM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Native Ligand</td>
<td>Tyr 662, Tyr 631, Arg 669, Arg 125, Trp 659, Val 711, Val 656, Val 546, His 740, Gly 628, Gly 632, Asp 545, Asn 710</td>
<td>0.463</td>
<td>-14.69</td>
<td>17.16</td>
</tr>
</tbody>
</table>

Geometry optimizations and comparison ligands were tested using Chemdraw ultra 12. The preparation was carried out using Autodock Tools 4.0.1 before in silico testing.

![Chemdraw ultra 12](image1.jpg)

![Chemdraw ultra 12](image2.jpg)

![Chemdraw ultra 12](image3.jpg)

![Chemdraw ultra 12](image4.jpg)
Figure 3: Structure of comparative ligands and test ligands (National, n.d.)
Then the docking of the comparative ligand and the test compound is carried out, belaying is done 100 times in one run. The result was chosen a conformation which has the most cluster members to see several parameters including free energy, inhibition constants and amino acids that interact and form bonds. The lowest free bond energy ($\Delta G$) shows the strongest interaction with the receptor. The inhibition constant ($K_I$) is a measure of the strength of the ligand in binding to the enzyme. Ligands with smaller $K_I$ values indicate greater binding affinity to inhibit the activity of an enzyme [10]. The bonds formed between DPP4 and each ligand are shown in Table 2.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Amino Acid Residue Interactions</th>
<th>$\Delta G$ (Kcal/mol)</th>
<th>$K_I$ (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitagliptin</td>
<td>Tyr 547, lys 554, trp 629, val 546, Arg 125, Asn 710</td>
<td>-7.49</td>
<td>3.25</td>
</tr>
<tr>
<td>Dulcoside-A</td>
<td>Trp 629, Val 546, Gly 632, Arg 125, Tyr 547</td>
<td>-5.29</td>
<td>133.26</td>
</tr>
<tr>
<td>Isosteviol</td>
<td>Lys 554, Arg 125</td>
<td>-8.44</td>
<td>0.652</td>
</tr>
<tr>
<td>Rebaudioside A</td>
<td>Lys 554, Trp 629, Tyr 662, Glu 205, Arg 125</td>
<td>-4.15</td>
<td>901.85</td>
</tr>
<tr>
<td>Rebaudioside B</td>
<td>Trp 629, Val 546, Arg 125, Ser 630, Asn 710</td>
<td>-4.52</td>
<td>483.19</td>
</tr>
<tr>
<td>Rebaudioside C</td>
<td>Val 546, Lys 554, Ser 630, Trp 629, Arg 125, Tyr 547, Glu 205</td>
<td>-5.10</td>
<td>182.61</td>
</tr>
<tr>
<td>Rebaudioside E</td>
<td>Trp 629, Tyr 547, Tyr 662, Glu 205, Arg 125</td>
<td>-4.02</td>
<td>1130</td>
</tr>
<tr>
<td>Steviol</td>
<td>Arg 125</td>
<td>-8.10</td>
<td>1.16</td>
</tr>
<tr>
<td>Steviolbioside</td>
<td>Tyr 662, Tyr 547, Glu 205, Lys 554</td>
<td>-7.33</td>
<td>4.27</td>
</tr>
<tr>
<td>Steviolmonoside</td>
<td>Arg 125, Tyr 547, Arg 669, Glu 206</td>
<td>-7.60</td>
<td>2.71</td>
</tr>
<tr>
<td>Stevioside</td>
<td>Lys 554, Trp 554, Tyr 662, Asn 710</td>
<td>-7.02</td>
<td>7.10</td>
</tr>
</tbody>
</table>

The docking results showed that there were 6 hydrogen bonds and 8 hydrophobic interactions between the DPP4 enzyme and the comparative ligand / sitagliptin (Figure 4). Isosteviol, steviol, and steviolmonoside compounds produce free bond energy and inhibition constants that are smaller than sitagliptin. As well as binding to several amino acid residues that are the same as sitagliptin (Figure 4,5,6,7). This shows that isosteviol, steviol, and steviolmonoside are potential candidates for antidiabetic drugs.
Figure 4: Visualization of sitagliptin 2D (a) and 3D (b) docking results on the DPP4 enzyme.

Figure 5: Visualization of isosteviol 2D (a) and 3D (b) docking results on the DPP4 enzyme.

Figure 6: Visualization of steviol 2D (a) and 3D (b) docking results on the DPP4 enzyme.

Figure 6: Visualization of steviolmonoside 2D (a) and 3D (b) docking results on the DPP4 enzyme.
Testing of pharmacokinetic parameters and toxicity was carried out through the pre-ADMET site. The results of the sitagliptin, isosteviol, steviol, and steviolmonoside compounds are presented in Table 3.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Absorption</th>
<th>Distribution</th>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Caco2 (nm.Sec-1)</td>
<td>HIA (%)</td>
<td>PPB (%)</td>
</tr>
<tr>
<td>Sitagliptin</td>
<td>21,6827</td>
<td>97,05249</td>
<td>54,32294</td>
</tr>
<tr>
<td>Isosteviol</td>
<td>19,7064</td>
<td>97,67445</td>
<td>100</td>
</tr>
<tr>
<td>Steviol</td>
<td>16,4437</td>
<td>95,24048</td>
<td>100</td>
</tr>
<tr>
<td>Steviolmonoside</td>
<td>14,6581</td>
<td>65,79098</td>
<td>80,44304</td>
</tr>
</tbody>
</table>

The results show that the three selected compounds have medium permeability to Caco-2 cells. Isosteviol and steviol compounds can be absorbed either through the digestive tract, comparable to sitagliptin. While steviolmonoside is included in moderate absorption. Isosteviol and steviol have a strong bond with plasma protein (PPB)> 90% strong bond while steviolmonoside is classified as weak.

**Lipinski’s rule of five** is a rule for evaluating the use of compounds as oral preparations. Where the parameters that must be met include a molecular weight of less than 500 Daltons, hydrogen bond acceptors not more than 5, hydrogen bond acceptors not more than 10, and LogP values not more than 5.15.

Of the 3 compounds that have been selected, it is known that the three compounds meet the Lipinski’s rule of five. So it can be stated that the three compounds can be used as drug candidates by oral use.

**CONCLUSION**

Based on the results of the study it can be concluded that the compounds contained in stevia leaves (Stevia rebaudiana Bertoni) in silico are able to interact with the DPP4 enzyme. Where compounds that have the potential to become candidates for antidiabetic drugs are isosteviol, steviol, and steviolmonoside. The compound binds to amino acid residues that also bind sitagliptin, namely Arginine (Arg 125). Lipinski rule of five prediction results show that both compounds meet the rules. Isosteviol has non carcinogenic and mutagenous characters while steviol and steviolmonoside have mutagenic characteristics such as comparative drugs.

**REFERENCES**

8. RSCB. 4ASS. [https://doi.org/http://dx.doi.org/10.2210/pdb4ASS/pdb](https://doi.org/http://dx.doi.org/10.2210/pdb4ASS/pdb).
